Acquisition by Agro Albert of 172189 shares of GRI BIO subject to Rule 16b-3

GRI Etf  USD 0.66  0.03  4.76%   
Under 55% of GRI Bio's traders are presently thinking to get in. The analysis of the overall investor sentiment regarding GRI Bio suggests that some traders are interested. GRI Bio's investing sentiment shows overall attitude of investors towards GRI Bio.
  
Filed transaction by Gri Bio Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
GRI insider trading alert for grant of common stock by Agro Albert, Chief Medical Officer, on 24th of April 2023. This event was filed by Gri Bio Inc with SEC on 2023-04-24. Statement of changes in beneficial ownership - SEC Form 4

GRI Bio Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards GRI Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

GRI Bio Fundamental Analysis

We analyze GRI Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GRI Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GRI Bio based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

GRI Bio is currently under evaluation in current ratio as compared to similar ETFs. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

GRI Bio Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GRI Bio etf to make a market-neutral strategy. Peer analysis of GRI Bio could also be used in its relative valuation, which is a method of valuing GRI Bio by comparing valuation metrics with similar companies.

Peers

GRI Bio Related Equities

PRLDPrelude Therapeutics   8.18   
0%
100.0%
HCWBHCW Biologics   7.69   
0%
94.0%
CUECue Biopharma   6.62   
0%
80.0%
GLUEMonte Rosa   3.26   
0%
39.0%
CELCCelcuity LLC   1.96   
0%
23.0%
AVTEAerovate Therapeutics   1.55   
0%
18.0%
XLOXilio Development   1.43   
0%
17.0%
HOWLWerewolf Therapeutics   0.75   
0%
9.0%
IKNAIkena Oncology   0.68   
0%
8.0%
EWTXEdgewise Therapeutics   0.07   
0%
1.0%
CNTBConnect Biopharma   1.02   
12.0%
0%
DSGNDesign Therapeutics   2.41   
29.0%
0%
ANEBAnebulo Pharmaceuticals   3.14   
38.0%
0%
GBIOGeneration Bio   3.70   
45.0%
0%
PASGPassage Bio   4.92   
60.0%
0%
CCCCC4 Therapeutics   5.71   
69.0%
0%
STTKShattuck Labs   7.20   
88.0%
0%

Other Information on Investing in GRI Etf

GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.